hemorrhage treatment report of patients suffering from glanzmann’s thrombasthenia resulting hospitalization from 2006 to 2011 at mofid children’s hospital

background: the present study evaluated treatment outcomes and the treatment indexes among glanzmann’s patients in mofid children’s hospital, tehran, iran. patients and methods: a retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 glanzmann’s patients with bleeding therapeutic records in mofid children’s hospital, tehran, iran, from 2006 to 2011. results: the total recombinant factor viia used was 137mg and the total infused platelet concentrates was 68 units, with platelets used in order being: apheresis platelets, leukoreduced pooled platelets, leukoreduced platelets, and random donor platelets with 35, 16, 13 and 4 units respectively. in 90% of bleeding sequences, leukoreduced platelets were available and the average admission per patient was 3.46 times, the average leukoreduced platelets consumption per patient was 4.26 units and the average use of recombinant factor viia per patient was 9.13mg. other indexes included the average hospitalization per patient per year of 0.69% times, the average consumption of non- random platelet per patient per year of 0.85% units, the average consumption of recombinant factor viia per patient per year of 1.83mg, the average consumption of non random platelet for any hemorrhage incidence or elective surgery of 1.3 units, and the average consumption of recombinant factor viia for any hemorrhage incidence of 2.8mg. conclusion: by extracting the consumption of therapeutical products to treat glanzmann’s thrombasthenia in our center we could estimate the future treatment needs of our medical center. more thorough investigation of patients from different age groups is recommended to achieve more reliable results. key words: glanzmann’s thrombasthenia, platelet, rfviia, treatment index.